BRIEF published on 09/24/2024 at 23:05, 2 years ago Theralase clôture un placement privé sans intermédiaire et émet des options sur actions Placement Privé Sans Intermédiaire Technologies Théralase Options Sur Actions Financement De La Recherche Clinique Étude Sur Le Cancer De La Vessie
BRIEF published on 09/24/2024 at 23:05, 2 years ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 2 years ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 2 years ago Theralase® prolonge ses mandats Extension Bourse De Croissance TSX Technologies Théralase Bons De Souscription D'actions Développement Pharmaceutique
BRIEF published on 09/19/2024 at 23:10, 2 years ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 2 years ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 2 years ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
BRIEF published on 09/03/2024 at 13:05, 2 years ago Ruvidar(TM) s'avère plus efficace que l'acyclovir dans la destruction du virus de l'herpès simplex Theralase Ruvidar Médicament Antiviral HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 2 years ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 2 years 1 month ago Rutherrin® augmente l'efficacité de la chimiothérapie contre le cancer du poumon Theralase® Technologies Inc. Chimiothérapie CPNPC Rutherrine® Cisplatine
Published on 10/01/2026 at 08:02, 57 minutes ago Southern Energy Announces Results of Annual Meeting and Board Changes
Published on 10/01/2026 at 01:21, 7 hours 38 minutes ago Revival Gold Announces Filing of Final Base Shelf Prospectus
Published on 10/01/2026 at 01:00, 7 hours 59 minutes ago Algo Grande Copper Secures Five-Year Surface Access Agreement With Ejido Palos Chinos at the Adelita Project
Published on 09/30/2026 at 23:30, 9 hours 29 minutes ago Early Warning News Release Issued with Respect to the Acquisition of Securities of Cypher Metaverse Inc.
Published on 09/30/2026 at 20:35, 12 hours 24 minutes ago Fairplay Ventures Inc. Enters Into Definitive Agreement to Complete Qualifying Transaction With Ampere Metals Pty. Limited
Published on 10/01/2026 at 08:35, 24 minutes ago European consumers dissatisfied with rising costs in cross-border online shopping reveals Nielsen IQ study, commissioned by agency KleinS
Published on 10/01/2026 at 08:33, 26 minutes ago Lenzing AG launches fully underwritten capital increase with subscription rights
Published on 10/01/2026 at 08:30, 29 minutes ago Eurazeo opens an office in Abu Dhabi, reinforcing its commitment to the Middle East
Published on 10/01/2026 at 08:30, 29 minutes ago Cegedim Business Services dévoile Hospi-DM, sa nouvelle offre SaaS de traçabilité des dispositifs médicaux, lors des 36èmes Journées Euro-Pharmat
Published on 10/01/2026 at 08:30, 29 minutes ago Eurazeo ouvre un bureau à Abu Dhabi et renforce son engagement au Moyen-Orient
Published on 10/01/2026 at 08:00, 59 minutes ago CNP Assurances and Embracon complete their combination to create a leading consórcio player in Brazil
Published on 10/01/2026 at 08:00, 59 minutes ago CNP Assurances et Embracon finalisent leur rapprochement pour former un acteur majeur du consórcio au Brésil
